IL211807A0 - Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment - Google Patents

Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Info

Publication number
IL211807A0
IL211807A0 IL211807A IL21180711A IL211807A0 IL 211807 A0 IL211807 A0 IL 211807A0 IL 211807 A IL211807 A IL 211807A IL 21180711 A IL21180711 A IL 21180711A IL 211807 A0 IL211807 A0 IL 211807A0
Authority
IL
Israel
Prior art keywords
fgfr
inhibitors
treatment
methods
growth factor
Prior art date
Application number
IL211807A
Other languages
English (en)
Original Assignee
Imclone Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imclone Llc filed Critical Imclone Llc
Publication of IL211807A0 publication Critical patent/IL211807A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL211807A 2008-10-20 2011-03-17 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment IL211807A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19685508P 2008-10-20 2008-10-20
PCT/US2009/060840 WO2010048026A2 (en) 2008-10-20 2009-10-15 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Publications (1)

Publication Number Publication Date
IL211807A0 true IL211807A0 (en) 2011-06-30

Family

ID=42062445

Family Applications (1)

Application Number Title Priority Date Filing Date
IL211807A IL211807A0 (en) 2008-10-20 2011-03-17 Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment

Country Status (17)

Country Link
US (3) US8043618B2 (OSRAM)
EP (1) EP2342232A2 (OSRAM)
JP (1) JP5577345B2 (OSRAM)
KR (1) KR101370798B1 (OSRAM)
CN (2) CN103524620A (OSRAM)
AR (1) AR073770A1 (OSRAM)
AU (1) AU2009307841B2 (OSRAM)
BR (1) BRPI0919832A8 (OSRAM)
CA (1) CA2741127C (OSRAM)
EA (1) EA021584B1 (OSRAM)
IL (1) IL211807A0 (OSRAM)
MX (1) MX2011004317A (OSRAM)
NZ (1) NZ592369A (OSRAM)
TW (1) TWI381848B (OSRAM)
UA (1) UA101681C2 (OSRAM)
WO (1) WO2010048026A2 (OSRAM)
ZA (1) ZA201101938B (OSRAM)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物
PE20120553A1 (es) 2009-03-25 2012-05-18 Genentech Inc Anticuerpos anti-fgfr3
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
EA201591324A1 (ru) 2013-01-16 2016-01-29 Инсерм (Энститю Насьональ Де Ля Сантэ Э Де Ля Решерш Медикаль) Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета
MX2015011428A (es) 2013-03-06 2016-02-03 Genentech Inc Metodos para tratar y prevenir la resistencia a los farmacos para el cancer.
TWI541022B (zh) * 2013-12-18 2016-07-11 應克隆公司 針對纖維母細胞生長因子受體－３（ｆｇｆｒ３）之化合物及治療方法
WO2015148708A1 (en) 2014-03-25 2015-10-01 Regeneron Pharmaceuticals, Inc. Fgf21 receptor agonists and uses thereof
WO2015187521A2 (en) * 2014-06-03 2015-12-10 Merck Sharp & Dohme Corp. Anti-blys antibodies
CN107073121A (zh) 2014-06-13 2017-08-18 基因泰克公司 治疗及预防癌症药物抗性的方法
EP3189341A4 (en) * 2014-09-05 2018-05-02 Hyperfine Research Inc. Ferromagnetic augmentation for magnetic resonance imaging
HUE058219T2 (hu) 2014-09-26 2022-07-28 Janssen Pharmaceutica Nv FGFR-mutánsgénpanel alkalmazása olyan rákbetegek azonosításában, akik FGFR-inhibitorral történõ kezelésre reszponzívak lesznek
CN107635583A (zh) * 2015-02-19 2018-01-26 生物临床医疗公司 用于治疗癌症的方法、组合物和试剂盒
EP3265462A1 (en) 2015-03-03 2018-01-10 INSERM - Institut National de la Santé et de la Recherche Médicale Fgfr3 antagonists
TW201711702A (zh) * 2015-06-04 2017-04-01 應克隆公司 使用針對纖維母細胞生長因子受體３（ｆｇｆｒ３）之化合物的療法
MA43416A (fr) 2015-12-11 2018-10-17 Regeneron Pharma Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3
EP3481859B1 (en) 2016-07-07 2022-04-13 Pfizer Inc. Soluble fibroblast growth factor receptor 3 (sfgfr3) polypeptides and uses thereof
US20180244785A1 (en) * 2017-01-09 2018-08-30 Merrimack Pharmaceuticals, Inc. Anti-fgfr antibodies and methods of use
US11505611B2 (en) 2020-08-21 2022-11-22 Genzyme Corporation FGFR3 antibodies and methods of use
CN114015770B (zh) * 2021-12-30 2022-04-26 佛山市第三人民医院(佛山市精神卫生中心) 精神分裂全外周血rna标志物fgfr3及其应用
EP4619438A2 (en) * 2022-11-14 2025-09-24 Regeneron Pharmaceuticals, Inc. Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes
WO2024152014A1 (en) 2023-01-13 2024-07-18 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof
WO2025240335A1 (en) 2024-05-13 2025-11-20 Regeneron Pharmaceuticals, Inc. Fgfr3 binding molecules and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
EP0318554B2 (en) 1987-05-21 2005-01-12 Micromet AG Targeted multifunctional proteins
IL159177A0 (en) * 2001-06-20 2004-06-01 Prochon Biotech Ltd Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20070248605A1 (en) * 2003-12-19 2007-10-25 Five Prime Therapetutics, Inc. Fibroblast Growth Factor Receptors 1,2,3, and 4 as Targets for Therapeutic Intervention
EP2024394B1 (en) * 2006-06-06 2014-11-05 Crucell Holland B.V. Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
HRP20130163T1 (hr) * 2006-09-07 2013-03-31 Crucell Holland B.V. Ljudske molekule za vezanje koje mogu neutralizirati virus influence h5n1 i njihova uporaba
WO2009054873A2 (en) * 2007-08-02 2009-04-30 Novimmune S.A. Anti-rantes antibodies and methods of use thereof
KR102269708B1 (ko) * 2008-04-11 2021-06-25 추가이 세이야쿠 가부시키가이샤 복수 분자의 항원에 반복 결합하는 항원 결합 분자
EP2313435A4 (en) * 2008-07-01 2012-08-08 Aveo Pharmaceuticals Inc FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) BINDING PROTEINS
TWI381848B (zh) * 2008-10-20 2013-01-11 Imclone Llc 抗纖維母細胞生長因子受體-3 (fgfr-3) 抗體及包含其之醫藥組合物

Also Published As

Publication number Publication date
EA201170590A1 (ru) 2011-10-31
BRPI0919832A8 (pt) 2019-01-08
JP2012505912A (ja) 2012-03-08
US8404240B2 (en) 2013-03-26
WO2010048026A3 (en) 2010-07-15
MX2011004317A (es) 2011-06-24
CA2741127C (en) 2015-06-02
AU2009307841A1 (en) 2010-04-29
CN103524620A (zh) 2014-01-22
EA021584B1 (ru) 2015-07-30
EP2342232A2 (en) 2011-07-13
AR073770A1 (es) 2010-12-01
US20120009200A1 (en) 2012-01-12
CN102186884A (zh) 2011-09-14
US20120219563A1 (en) 2012-08-30
CN102186884B (zh) 2014-08-13
US8043618B2 (en) 2011-10-25
TW201026325A (en) 2010-07-16
WO2010048026A2 (en) 2010-04-29
TWI381848B (zh) 2013-01-11
UA101681C2 (ru) 2013-04-25
KR20110056554A (ko) 2011-05-30
NZ592369A (en) 2013-02-22
AU2009307841B2 (en) 2013-09-12
JP5577345B2 (ja) 2014-08-20
US20100098696A1 (en) 2010-04-22
ZA201101938B (en) 2012-08-29
KR101370798B1 (ko) 2014-03-14
BRPI0919832A2 (pt) 2015-12-15
CA2741127A1 (en) 2010-04-29
US8182815B2 (en) 2012-05-22

Similar Documents

Publication Publication Date Title
ZA201101938B (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
IL213068A0 (en) Pyridyloxyindoles inhibitors of vegf-r2 and use thereof for treatment of disease
EP2352452A4 (en) SYSTEMS AND METHOD FOR TREATING PROSTATE TISSUE
PL2352453T3 (pl) Układy i sposoby leczenia tkanki gruczołu krokowego
EP2262450A4 (en) IMPLANTS AND METHODS OF USE
IL216140A0 (en) Egfr inhibitors and methods of treating disorders
EP2019679A4 (en) GLUCOSE TRANSPORT AND APPLICATION METHOD
IL194820A0 (en) Devices and methods for treatment of tissue
ZA201100211B (en) Kinase inhibitors and methods of use
EP2252293A4 (en) KINASEHEMMER AND USE PROCESS
EP2424857A4 (en) DOUBLE ACTION INHIBITORS AND METHODS OF USE
EP2249914A4 (en) IMPLANT EQUIPPED FOR NERVE LOCATION AND METHOD OF USE
SI2379096T1 (sl) Zaviralci TFPI in postopki uporabe
EP2170180A4 (en) METHOD AND DEVICES FOR TREATING VESSELS AND PROSTATE
IL212079A0 (en) Methods and devices for treating sleep apnea
GB0821927D0 (en) Article and method of surface treatment of an article
IL207132A0 (en) Composition and method for seed treatment use
HUE036609T2 (hu) Eljárás és készítmények rák kezelésére
EP2493550A4 (en) ELECTRO-OPTICAL FABRIC STIMULATOR AND METHOD OF USE THEREOF
IL220147A0 (en) Inhibitors of vascular endothelial growth factor (vegf) receptro and methods of use thereof
EP2376083A4 (en) QUINAZOLIN-BASED BACE-1 INHIBITORS AND METHODS OF USE
GB2463474B (en) Therapeutic bone growth and regeneration
WO2009151620A9 (en) Pain treatment using erk2 inhibitors
HK1156641A (en) Fibroblast growth factor receptor-3 (fgfr-3) inhibitors and methods of treatment
GB0800556D0 (en) Method of treatment and treatment therefor